Phase III pivotal study of PF 04965842 shows efficacy and safety in atopic dermatitis

Pfizer announced positive top-line results from a Phase III pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor PF 04965842 (abrocitinib ) in patients aged 12 and older with moderate to severe atopic dermatitis (AD). B7451012 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12 weeks. Top-line results showed that by week 12 the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo. In addition, the results demonstrate response to treatment for a statistically significant number of patients during the first two to four weeks following first dose.

The co-primary study endpoints were the proportion of patients who achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin and at least 2 point improvement; and the proportion of patients who achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score. The key secondary endpoints were the proportion of patients achieving a 4 point or larger reduction in itch severity measured with the pruritus numerical rating scale (NRS) and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD). Safety results show that both doses of abrocitinib were well-tolerated, and there were no unexpected safety events. The discontinuation rates due to an adverse event were low in each treatment arm (5.8% and 5.8% in 100mg and 200mg) compared to placebo (9.1%).

Comment: Detailed analyses of B7451012, including additional efficacy and safety data, will be submitted for presentation at a future scientific meeting and published in a prominent medical journal. B7451012 is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program. Additional data from another study in the JADE program will be available later this year.